Introduction {#sec1}
============

The most suitable strategy for the treatment of patients with papillary thyroid cancer (PTC) is total thyroidectomy along with the dissection of all clinically apparent metastatic lymph nodes. There is considerable controversy concerning the approach to lymphadenectomy in PTC patients with clinically N0 lymph nodes. The incidence of lymph node metastases is relatively high in PTC patients, even in the presence of small tumors, so the likelihood of local relapse can be reduced by routine central lymphadenectomy. However, routine central compartment lymph node dissection causes more recurrent laryngeal nerve damage and permanent hypoparathyroidism. Therefore, some surgeons perform selective lymphadenectomy of the central compartments only when there is evidence of lymph node involvement.

Nowadays, sentinel lymph node (SLN) biopsy is commonly applied in melanoma and breast cancer patients, but its use is investigated in other types of solid tumors, including PTC. According to the concept of SLN, that lymph node is the first node affected by metastasis, and if it can be shown to be negative it is highly unlikely that others lymph nodes are affected. Thus, SLN biopsy allows the number of complications associated with unnecessary lymph node dissection to be reduced. The SLN in PTC patients should be evaluated intraoperatively to avoid a potentially more difficult reoperation of the neck. There are several methods for the intraoperative evaluation of lymph nodes, such as frozen section, imprint biopsy and molecular techniques.

To the best of our knowledge, thyroid lymph nodes have only been examined by means of frozen section \[[@cit0001], [@cit0002]\]. Frozen section examination has two shortcomings: it gives false negative results for up to 23.3% of positive SLNs \[[@cit0001]\]; and it has limited specificity in detecting micrometastases \[[@cit0003]\]. Additionally, this examination cannot be performed in many hospitals because pathological examinations are outsourced to other hospitals or pathological centers. Therefore, there is a need to search for new, automated methods for the evaluation of lymph nodes. Probably, as in other cancer types, the addition of molecular techniques to standard histopathology should improve the accuracy of the intraoperative assessment of SLNs in thyroid carcinoma \[[@cit0004]--[@cit0008]\].

A number of molecular diagnostic assays based on the quantitative reverse transcription polymerase chain reaction have been developed for the intra-operative diagnosis of lymph node metastases. These methods can examine the whole lymph nodes and are expected to become an alternative to conventional histological examination. However, these tests are not used in routine practice, probably because they are complex and time-consuming. Therefore, hematoxylin and eosin staining continues to be the gold standard in lymph node evaluation. The one-step nucleic acid (OSNA) assay is a recently introduced molecular method, which is based on reverse transcription loop mediated isothermal amplification (RT-LAMP) of cytokeratin 19 (CK19) mRNA as its sole marker. That technique was invented by Notomi *et al.* \[[@cit0009]\]. In this system, the CK19 mRNA is directly and rapidly amplified from the supernatant of homogenized lymph nodes. Neither purifying mRNA nor changing temperatures during amplification are needed, unlike in PCR, so the results are available within 30 min and four lymph nodes can be simultaneously analyzed. The OSNA procedure is automated and can be performed even in an operating theatre. The first application of OSNA was presented by Tsujimoto *et al.* for breast cancer. The compliance rate of the intraoperative histopathological examination and OSNA assay was 98.2% for all lymph nodes, including 96.4% for sentinel lymph nodes \[[@cit0010]\]. That technique has become a real alternative to the standard histopathological examination in Spain \[[@cit0011]\]. Its utility has been examined in other cancers. The OSNA appears to be a promising tool for the detection of lymph node micro- and macrometastases in sentinel lymph nodes in colorectal cancer patients \[[@cit0012]\]. It resulted in upstaging of 15.3% to 25.2% of colon cancer patients with negative lymph nodes after standard H&E examination \[[@cit0012]--[@cit0014]\]. This technique showed the sensitivity of lymph node metastasis detection in gastric cancer patients as high as that of the histological examination of blocks sectioned at 2-mm intervals \[[@cit0015]\].

The OSNA is already being applied in many malignant neoplasms: lung cancer, head and neck squamous cancer, endometrial cancer and cervical cancer \[[@cit0015]--[@cit0021]\]. The OSNA technique was evaluated in two studies on thyroid cancer patients. Their results for the detection of sentinel lymph nodes were similar to those obtained using standard histopathology or molecular techniques \[[@cit0022], [@cit0023]\]. The aim of the study is to determine the efficacy of OSNA and SLN biopsy in the intraoperative detection of nodal involvement. To the best of our knowledge, it is the first publication concerning this matter in thyroid cancer.

Material and methods {#sec2}
====================

General information {#sec2.1}
-------------------

This research was designed as a prospective, experimental study. The Ethical Commission of the Medical University of Lodz approved the study protocol.

The study was done in compliance with the Declaration of Helsinki.

All patients were informed about the investigational purpose of the procedure and provided their written informed consent. This prospective study enrolled 49 patients who underwent total thyroidectomy and elective bilateral central lymph node dissection (level VI according to the WHO classification) with or without lateral lymph node dissection (levels II--V according to the WHO classification). The results of the OSNA assay did not affect the operative procedure.

The kind of the operation was in accordance with the guidelines of most surgical societies \[[@cit0024], [@cit0025]\].

All operations were performed by two experienced endocrine surgeons (more than 50 thyroid operations a year). The patients were suspected of or diagnosed with thyroid carcinoma based on fine needle aspiration biopsy (FNAB) before the operation. Only patients primarily operated on were included in the study.

On clinical examination, all patients had clinically negative lymph nodes. All patients also underwent thyroid and neck ultrasonography, and no patient had evidence of lymph node enlargement.

Exclusion criteria included: evidence of lymph node involvement, clinically evident local or distant metastases, macroscopically infiltrating tumors, benign thyroid disease, a history of previous neck surgery, radioiodine treatment before the operation, pregnancy or active breastfeeding, and significant comorbidities.

Surgical technique {#sec2.2}
------------------

The procedure was performed with the patients under general anesthesia as follows. after a standard transverse cervical incision had been made, cutaneous flaps were developed. The thyroid gland was exposed by the separation and lateralization of the strap muscles. Parathyroid glands were identified. Subsequently, 1% Patent Blue dye (Guerbet GmbH Germany) was injected intratumorally, very slowly, under low pressure, using a 27-G needle and insulin syringe. Care was taken not to accidentally stain the surrounding structures. 0.5 ml was injected if the diameter was 2 cm or below. 1 ml of blue dye was used for tumors larger than 2 cm. Lymph nodes that stained blue were defined as SLNs. Data were recorded with respect to the lymph node size, number, and anatomical localization. Frozen section examination was not performed.

Lymph nodes workup {#sec2.3}
------------------

Lymph nodes ≥ 5 mm in the greatest dimension were included in the study for histopathology as well as OSNA. The cutoff size of 5 mm was chosen for technical reasons. If the lymph nodes are smaller than 5 mm, then it is technically impossible to cut lymph nodes into 4 blocks and perform histopathological and molecular analysis. These lymph nodes were investigated only by histopathology. Lymph nodes were meticulously harvested from the fatty tissue and directly cut into blocks at 2-mm intervals with cutting devices developed by Tsujimoto *et al.* \[[@cit0010]\].

Nonadjacent blocks were subjected to either the OSNA assay or histological examination. Blocks for the OSNA were pooled and analyzed together. They were shock-frozen in liquid nitrogen and stored at --70°C until molecular analysis was performed. The other blocks were cut and stained with hematoxylin and eosin, and analyzed by histological examination.

Histopathology procedure {#sec2.4}
------------------------

The final histological examination consisted in a detailed analysis of the lymph node tissue sections embedded in paraffin blocks. All specimens were examined by experienced specialists in clinical pathology, using a conventional optical microscope. To ensure objectivity, the final histological results were based on the conclusions of two independent pathologists, blinded to OSNA results. Any evidence of metastatic cellularity was considered to be positive for lymphatic dissemination.

OSNA procedure {#sec2.5}
--------------

The OSNA examination for each lymph node included the homogenization of tissue in a mRNA-stabilizing solution and subsequent amplification. It was performed automatically by the reverse transcription loop-mediated isothermal amplification (RT-LAMP) of CK19 mRNA in the RD-100i detection engine (Sysmex) without prior mRNA isolation and purification as recommended for OSNA elsewhere. The RD-100i system includes a ready-to-use reagent kit (Lynoamp, Sysmex) consisting of the enzyme, primers, nucleotides, buffer necessary for CK19 mRNA amplification and components for assay validation (calibrators, positive and negative controls). The technique uses six primers, which increase the specificity and speed of the reaction. The expression level of CK19 mRNA is detected by the real-time monitoring of turbidity changes caused by an increase in the concentration of magnesium pyrophosphate, a by-product of the amplification reaction. It is possible to analyze up to 4 SLNs at the same time. The SLN was assessed as OSNA (+) when the CK 19 mRNA copy number was more than 2.5 × 10^2^ copies/μl.

Results {#sec3}
=======

The SLNs were found in 43 (87.8%) of 49 primarily included patients.

A further analysis was carried out only in the group of patients with detected SLNs. The mean age of the investigated group was 50.1 years. There were 10 men and 33 women (F/M ratio was 4.3/1). Thirty-eight (88.4%) patients were diagnosed with the classical variant of papillary thyroid cancer (CVPC) and 5 (11.6%) with the follicular variant of papillary thyroid cancer ([Tables I](#t0001){ref-type="table"} and [II](#t0002){ref-type="table"}).

###### 

TNM staging of included patients

  TNM staging      No. of patients (%)
  ---------------- ---------------------
  T~1a~N~0~M~0~    6 (13.9)
  T~1am~N~0~M~0~   1 (2.3)
  T~1b~N~0~M~0~    11 (25.6)
  T~2~N~0~M~0~     10 (23.3)
  T~1a~N~1a~M~0~   3 (7.0)
  T~1b~N~1b~M~0~   2 (4.7)
  T~2~N~1a~M~0~    5 (11.6)
  T~2~N~1b~M~0~    2 (4.7)
  T~3~N~1a~M~0~    1 (2.3)
  T~3~N~1b~M~0~    2 (4.7)

###### 

Original data for study subjects

  No.   Age \[years\]   Sex   Clinical stage   Histologic type   Site   Tumor size \[mm\]
  ----- --------------- ----- ---------------- ----------------- ------ -------------------
  1     41              F     T~2~N~1a~M~0~    CVPC              RL     30
  2     43              M     T~1b~N~0~M~0~    CVPC              LL     20
  3     50              F     T~1a~N~0~M~0~    CVPC              RL     7
  4     49              F     T~1a~N~0~M~0~    CVPC              RL     9
  5     65              F     T~1am~N~0~M~0~   CVPC              RR     2 and 7
  6     68              M     T~1b~N~1b~M~0~   CVPC              LL     20
  7     47              F     T~1b~N~0~M~0~    CVPC              RL     18
  8     37              F     T~2~N~1b~M~0~    CVPC              LL     25
  9     73              F     T~1b~N~0~M~0~    CVPC              LL     20
  10    47              M     T~2~N~1a~M~0~    CVPC              LL     30
  11    34              F     T~1a~N~1a~M~0~   FVPC              RL     20
  12    65              F     T~3~N~1b~M~0~    CVPC              LL     9
  13    71              M     T~2~N~0~M~0~     CVPC              RL     25
  14    43              F     T~1b~N~0~M~0~    CVPC              RL     20
  15    53              F     T~1a~N~1a~M~0~   CVPC              LL     15
  16    54              F     T~2~N~0~M~0~     CVPC              RL     23
  17    45              F     T~1b~N~0~M~0~    CVPC              RL     12
  18    56              F     T~1a~N~0~M~0~    CVPC              RL     8
  19    43              F     T~2~N~1a~M~0~    CVPC              LL     28
  20    19              M     T~3~N~1b~M~0~    CVPC              LL     12
  21    49              F     T~2~N~1a~M~0~    CVPC              LL     26
  22    54              F     T~1a~N~1a~M~0~   CVPC              RL     16
  23    34              F     T~1a~N~0~M~0~    CVPC              LL     6
  24    46              F     T~2~N~0~M~0~     CVPC              RL     24
  25    71              F     T~2~N~1a~M~0~    FVPC              RL     31
  26    29              F     T~1b~N~0~M~0~    CVPC              LL     11
  27    68              F     T~2~N~1b~M~0~    CVPC              RL     24
  28    67              F     T~2~N~0~M~0~     FVPC              LL     27
  29    56              F     T~1b~N~0~M~0~    CVPC              RL     14
  30    48              F     T~3~N~1a~M~0~    CVPC              LL     7
  31    23              M     T~1b~N~1b~M~0~   CVPC              LL     15
  32    28              F     T~1b~N~0~M~0~    CVPC              RL     19
  33    56              F     T~1b~N~1a~M~0~   CVPC              I/RL   14
  34    71              M     T~2~N~0~M~0~     CVPC              RL1    28
  35    63              F     T~2~N~0~M~0~     CVPC              LL     21
  36    40              F     T~1b~N~0~M~0~    CVPC              RL     16
  37    28              F     T~2~N~0~M~0~     FVPC              LL     24
  38    43              F     T~2~N~0~M~0~     CVPC              LL     29
  39    59              M     T~2~N~0~M~0~     CVPC              RL     34
  40    74              M     T~1b~N~0~M~0~    FVPC              RL     18
  41    54              F     T~1a~N~0~M~0~    CVPC              RL     6
  42    38              M     T~2~N~0~M~0~     CVPC              RL     31
  43    52              F     T~1a~N~0~M~0~    CVPC              LL     8

F -- female, M -- male, CVPC -- classical variant of papillary thyroid cancer, FVPC -- follicular variant of papillary thyroid cancer, RL -- right lobe, LL -- left lobe.

Distribution of sentinel lymph nodes {#sec3.1}
------------------------------------

There were found 65 SLNs. The number of SLNs ranged from 1 to 4 (mean 1.5 per patient). In terms of SLN distribution in the neck, 55 (84.6%) of all the SLNs were located in the central compartment area ([Figure 1](#f0001){ref-type="fig"}).

![Distribution of SLNs and histopathology and OSNA results\
H+ -- positive result of histopathology examination, H-- -- negative results of histopathology examination, O+ -- positive result of OSNA examination, O-- -- negative results of OSNA examination, RCC -- right central compartment (level VI according to the WHO classification), LCC -- left central compartment (level VI according to the WHO classification), RLCs -- right lateral compartments (levels II--V according to the WHO classification), LLCs -- left lateral compartments (levels II--V according to the WHO classification), UM -- upper mediastinum.](AMS-13-29244-g001){#f0001}

Twenty-one (32.3%) of them were situated in the right central compartment on the same side of the tumor. Thirty (46.2%) SLNs were found in the left central compartment on the same side of the tumor. There were 4 (6.2%) SLNs on the opposite side with respect to the tumor: 3 (4.6%) in the left central compartment and 1 (1.5%) in the right compartment ([Figure 1](#f0001){ref-type="fig"}).

Ten SLNs were found only outside the central compartment. Three patients had 2, 3 and 1 SLNs respectively in the right lateral compartment. One patient had 2 SLNs in the upper mediastinum. Two patients had 1 SLN in two compartments: the central and left lateral.

Histopathology and OSNA results of SLNs {#sec3.2}
---------------------------------------

There were 20 (30.8%) histopathologically positive SLNs. According to the OSNA assay, 22 (33.8%) SLNs were positive. The OSNA results were different from histopathology in 8 (12.3%) SLNs ([Figure 1](#f0001){ref-type="fig"}). The OSNA assay gave a positive result in 5 (7.7%) SLNs, while they were not involved according to histopathology.

The OSNA upstaged N status from N0 to N1 only in 2 patients ([Figure 2](#f0002){ref-type="fig"}, [Table III](#t0003){ref-type="table"}). Inverse results (histopathology +, OSNA--) were obtained in 3(4.6%) SLNs. OSNA downstaged N status from N1 to NO in only 1 patient ([Figure 2](#f0002){ref-type="fig"}, [Table III](#t0003){ref-type="table"}). In our series PPV and NPV for OSNA were 0.77 and 0.93, respectively. The concordance rate between examinations was 85.5%.

###### 

Localization of SLNs and their histopathology and OSNA results

  -----------------------------------------------------------------------------------------------
  Patient   Examination             Number of metastatic/total SLNs                        
  --------- ----------------------- --------------------------------- ------ ------ ------ ------
  1         Histopathology\         2/2\                                                   
            OSNA                    2/2                                                    

  2         Histopathology\                                           0/1\                 
            OSNA                                                      0/1                  

  3         Histopathology\                                           0/1\                 
            OSNA                                                      0/1                  

  4         Histopathology\                                                  0/2\          
            OSNA                                                             0/2           

  5         Histopathology\         0/1\                                                   
            OSNA                    0/1                                                    

  6         Histopathology\                                           1/1\                 
            OSNA                                                      1/1                  

  7         Histopathology\         0/2\                                                   
            OSNA                    0/2                                                    

  8         Histopathology\                                           1/2\          1/1\   
            OSNA                                                      2/2           1/1    

  9         Histopathology\                                           0/1\          0/1\   
            OSNA                                                      0/1           0/1    

  10        Histopathology\                                           1/2\                 
            OSNA                                                      2/2                  

  11        Histopathology\         1/1\                                                   
            OSNA                    1/1                                                    

  12        Histopathology\                                           0/1\                 
            OSNA                                                      0/1                  

  13        Histopathology\         0/2\                                                   
            OSNA                    0/2                                                    

  14        Histopathology\         0/1\                                                   
            OSNA                    0/1                                                    

  15        Histopathology\                                           2/3\                 
            OSNA                                                      1/3                  

  16        Histopathology\                                                  0/3\          
            OSNA                                                             0/3           

  17        Histopathology\         0/1\                                                   
            OSNA                    0/1                                                    

  18        Histopathology\         0/1\                                                   
            OSNA                    0/1                                                    

  19        Histopathology\                                           2/2\                 
            OSNA                                                      2/2                  

  20        Histopathology\                                           1/2\                 
            OSNA                                                      1/2                  

  21        Histopathology\                                           0/1\                 
            OSNA                                                      0/1                  

  22        Histopathology\                                           2/2\                 
            OSNA                                                      2/2                  

  23        Histopathology\         0/1\                              0/3\                 
            OSNA1                   1/1                               0/3                  

  24        Histopathology\                                           0/1\                 
            OSNA                                                      0/1                  

  25        Histopathology\                                           0/1\                 
            OSNA                                                      0/1                  

  26        Histopathology\         2/2\                                                   
            OSNA                    1/2                                                    

  27        Histopathology\         0/1\                              0/1\                 
            OSNA                    0/1                               0/1                  

  28        Histopathology\         1/1\                                                   
            OSNA                    1/1                                                    

  29        Histopathology\                                           0/1\                 
            OSNA                                                      0/1                  

  30        Histopathology\         0/1\                                                   
            OSNA                    0/1                                                    

  31        Histopathology\                                           1/2\                 
            OSNA                                                      0/2                  

  32        Histopathology\                                           1/2\                 
            OSNA                                                      1/2                  

  33        Histopathology\                                           1/2\                 
            OSNA                                                      2/2                  

  34        Histopathology\         0/1\                                                   
            OSNA                    0/1                                                    

  35        Histopathology\                                                                0/2\
            OSNA                                                                           0/2

  36        Histopathology\         0/1\                                                   
            OSNA                    0/1                                                    

  37        Histopathology\                                           0/1\                 
            OSNA                                                      0/1                  

  38        Histopathology\         0/1\                                                   
            OSNA                    1/1                                                    

  39        Histopathology\         0/1\                                                   
            OSNA                    0/1                                                    

  40        Histopathology\                                           0/2\                 
            OSNA                                                      0/2                  

  41        Histopathology\                                                  0/1\          
            OSNA                                                             0/1           

  42        Histopathology OSNA13   0/1\                                                   
                                    0/1                                                    

  43        Histopathology OSNA                                       0/1\                 
                                                                      0/1                  
  -----------------------------------------------------------------------------------------------

RCC -- right central compartment, LCC -- left central compartment, RLCs -- right lateral compartments, LLCs -- left lateral compartments, UM -- upper mediastinum.

![Potential impact of SLNB and OSNA results on TNM status](AMS-13-29244-g002){#f0002}

Discussion {#sec4}
==========

The biopsy of the SLN is not a standard procedure in thyroid cancer. In 1998, Kelemen *et al.* first described the use of the dye method in mapping the SLN in thyroid cancer. The sentinel lymph node was found in 15 out of 17 patients enrolled in the study, including all the 12 patients postoperatively diagnosed with thyroid cancer.

Five of those had metastases in lymph nodes \[[@cit0026]\]. In 1999, Gallowitsch *et al.* and subsequently, in 2001, Sahin *et al.* applied the radioisotope method to localize the SLN in thyroid cancer patients \[[@cit0027], [@cit0028]\]. However, until now, in a majority of cases of sentinel lymph node mapping in thyroid carcinoma, the dye method has solely been employed \[[@cit0029], [@cit0030]\]. Similarly to breast cancer or melanoma, routine SLN biopsies could bring several potential benefits. Those benefits, however, are the greatest when the detected SLNs are assessed using a reliable intraoperative method. The best would be a quantitative, automated method applying an easily operated device. Perhaps such a method will be the OSNA assay. Therefore, the aim of this study was to evaluate the usefulness of the sentinel lymph node biopsy and OSNA method in determining the extent of lymph node removal in thyroid cancer patients. In our study, 65 SLNs were detected in 43 patients. The percentage of patients with detected SLNs did not differ from results obtained by other researchers. Except for the study by Peparini *et al.*, conducted on a very small group of patients, the percentage has always exceeded 60% \[[@cit0031]\]. It was above 90% in many studies \[[@cit0030]--[@cit0032]\]. In a meta-analysis done by the authors of this study, it was found that the detection rate of the sentinel lymph node using patent blue was 68.3% \[[@cit0032]\]. Perhaps applying another method, along with the dye method, in localizing the SLN would result in an increased percentage of patients in whom the SLN would be found. However, in thyroid cancer, less commonly than in other cancers, the radioisotope method is used to detect the SLN.

The introduction of the sentinel lymph node biopsy, as a standard procedure, in thyroid cancer could bring several potential benefits. However, only the simultaneous application of the sentinel lymph node biopsy and intraoperative lymph node assessment method would contribute to the enhancement of their benefits. At present, OSNA is the most popular intraoperative molecular lymph node assessment method. Potential benefits may accrue from the simultaneous application of both the methods.

It may reduce the number of unnecessary lymphadenectomies and thus postoperative hypoparathyroidism and recurrent laryngeal nerve paralysis cases. In our study, histopathology showed metastases in 20 (30.8%) SLNs in 11 (2.56%) patients. There were 22 (33.8%) OSNA-positive SLNs. The concordance rate between histopathology and OSNA was 85.5%. The OSNA results were different from histopathology in only 8 (12.3%) SLNs.

Three of them were OSNA-positive and histopathologically negative, but the OSNA examination determined TNM staging (N status) lower than histopathology in only 1 person (patient 31 -- [Table III](#t0003){ref-type="table"}). The OSNA assay gave positive results in 5 (7.7%) SLNs, while they were not affected according to histopathology. However, only in 2 cases (patient 23 and 38) did OSNA upstage the N status from N0 to N1.

As there was no reliable intraoperative examination, we performed central lymphadenectomy in all patients. If we consider histopathology the gold standard, it was done unnecessarily in 29 (67.4%) of 43 patients with clinically negative lymph nodes which were negative in histopathology.

If we had relied on the SLNB and OSNA combination, 28 (65.1%) patients would not have had any lymphadenectomy done. Among this group of patients, only in 1 (3.6%) would lymph node metastases have been left.

In some thyroid cancer patients there may occur the phenomenon of skip metastases, i.e., the presence of thyroid cancer metastases in lateral nodes with metastasis-free lymph nodes of the central compartment. They can be observed in approximately one-fifth of patients \[[@cit0033]--[@cit0035]\]. The presence of skip metastases may result from the presence of alternative lymph drainage routes from the primary focus or disturbed outflow from the primary focus due to postinflammatory, postirradiation or posttraumatic, including postoperative, lesions \[[@cit0036]\]. The above suggests that elective lymphadenectomy should preferably be performed in the lateral compartment of the neck. Perhaps the introduction of the sentinel lymph node biopsy would enable identification of a group of patients in whom the nodes of the lateral compartment of the neck ought to be removed. Paradoxically, in such cases, the SLNB expands the scope of the lymphadenectomy. The usefulness of applying the SLNB for such a purpose has been proved. Chow *et al.* found sentinel lymph nodes solely in the lateral compartment in 10% of patients. In others, sentinel lymph nodes were located in both the lateral and central compartments \[[@cit0037]\]. In our study, the presence of sentinel lymph nodes in the lateral compartments of the neck was detected in 3 (7.0%) patients. In 2 of those, no neoplastic cells were found in histopathology and the OSNA results were not positive.

In 1 patient, two sentinel lymph nodes were detected in the central compartment and one in the lateral compartment. Histopathology indicated metastases in all those nodes. Positive OSNA results were obtained for one node from the central and one from the lateral compartment. Based on the OSNA, despite the detection of sentinel lymph nodes outside the central compartment in 2 of 3 patients, only one would have undergone lateral lymphadenectomy.

The SLNB and intraoperative examination may help to determine the appropriate treatment of follicular tumors. Such an application of the sentinel lymph node biopsy was presented by Takeyama *et al.* \[[@cit0038]\]. In patients with preoperatively diagnosed follicular tumor, the sentinel lymph node biopsy and intraoperative frozen sample examination enable one to determine the scope of the primary procedure. The negative result of the intraoperative examination allows one to avoid performing central lymphadenectomy regardless of whether the patient will ultimately be diagnosed with follicular cancer or follicular tumor. The positive result of the intraoperative sentinel lymph node material examination is tantamount to the diagnosis of cancer and makes lymphadenectomy necessary. In many hospitals where it is not possible to perform frozen section, OSNA could be an alternative to that intraoperative examination. We did not include patients with follicular tumors. However, we obtained a high percentage of detected SLN (87.8%) and a low percentage of false negative OSNA results -- only for 1 (2.3%) patient. Perhaps the combination of SLNB and OSNA may be used to determine the extent of surgery for follicular neoplasms.

It is laborious and expensive to perform molecular tests on material collected from all lymph nodes. The sentinel lymph node biopsy allows one to focus on one or two lymph nodes representative of all others. In large bowel cancer patients, such a procedure enabled a higher stage of the disease to be diagnosed \[[@cit0039]\].

In thyroid cancer, relapse occurs in a large number of patients despite the negative histopathology of lymph nodes. Perhaps the application of sentinel lymph node biopsy and OSNA may allow identification of a group of patients at a higher risk of relapse (histopathologically negative, OSNA positive). Perhaps those patients should be administered radioactive iodine. There were two such patients among our patients. They are in follow-up and have had no recurrence. Further studies should find a larger group of such patients to draw any conclusion.

In conclusion, it can be stated that it is relatively technically easy to perform the SLNB and OSNA. In some of the patients with clinically negative lymph nodes, the employment of those procedures may prevent unnecessary central lymphadenectomy and associated increased risk of recurrent laryngeal nerve and parathyroid gland damage. On the other hand, the sentinel lymph node biopsy may reveal the presence of potentially involved sentinel lymph nodes outside the central compartment. Similarly to the central compartment lymph nodes, those nodes can be assessed by means of OSNA. The application of OSNA in such a case may allow the extent of lymphadenectomy to be determined.
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